Christopher B. Prentiss serves as the Chief Financial Officer at MannKind Corporation, a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes. With a robust background in finance and strategic planning, Prentiss has been instrumental in guiding MannKind's financial strategy and growth initiatives. He joined the company in 2017, bringing with him extensive experience in the pharmaceutical industry. Prior to his role at MannKind, Prentiss held several senior financial positions at leading healthcare companies. He spent over a decade at Bristol-Myers Squibb, where he progressed through various roles, eventually serving as the Vice President of Finance for their U.S. pharmaceuticals business. During his tenure, he was recognized for his ability to drive financial performance and implement cost-effective strategies that supported the company's growth objectives. Prentiss also worked at Pfizer, where he honed his skills in financial planning and analysis, contributing to the successful launch of several blockbuster drugs. As CFO at MannKind, Prentiss is responsible for overseeing all aspects of the company's financial operations, including accounting, budgeting, and investor relations. Under his leadership, MannKind has strengthened its financial position, enabling the company to invest in research and development and expand its product portfolio. Prentiss's strategic vision and financial acumen have been pivotal in navigating the complex landscape of the biopharmaceutical industry, ensuring that MannKind remains at the forefront of innovation in diabetes care.